☆ 4.6 Article

Long term treatment of rheumatoid arthritis with rituximab

AUTOIMMUNITY REVIEWS (2009)

期刊

AUTOIMMUNITY REVIEWS

卷 8, 期 7, 页码 591-594

出版社

ELSEVIER SCIENCE BV

DOI: 10.1016/j.autrev.2009.02.008

关键词

Rheumatoid arthritis; B-lymphocyte; Rituximab

类别

Immunology

向作者/读者索取更多资源

Protocol

Reagent

摘要

B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). Rituximab is a chimeric monoclonal antibody that depletes B-cells by binding to the CD20 surface antigen that has been approved for the treatment of RA. Its efficacy has been clearly demonstrated by different clinical trials and, recently, in long-term observational studies. The use of rituximab in clinical practice has highlighted its efficacy and safety over more than 5 years of treatment, as well as to try to understand the timing for retreatment of patients relapsing after a good initial response. (C) 2009 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Rheumatology

Should complete B cell depletion be maintained in patients treated long-term with rituximab for rheumatoid arthritis?

Roba Ghossan, Omar Al Tabaa, Alice Combier, Alexia Steelandt, Marion Thomas, Olivier Fogel, Corinne Miceli-Richard, Anna Molto, Yannick Allanore, Jerome Avouac

Summary: Maintaining complete B cell (BC) depletion does not appear to be a therapeutic target to achieve in rheumatoid arthritis (RA) patients in long-term maintenance therapy with rituximab (RTX).

RHEUMATOLOGY (2023)

添加到收藏夹

Article Immunology

Mechanistic insights into the role of B cells in rheumatoid arthritis

Anuja Singh, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Tanveer Naved, Saurabh Bhatia, Ahmed Al-Harrasi, Prasun Chakrabarti, Lotfi Aleya, Celia Vargas-De-La-Cruz, Simona Bungau

Summary: Rheumatoid arthritis is an autoimmune disease characterized by severe inflammation that damages tendons, cartilage, and bones. B cells play a significant role in the pathogenesis of RA, and targeting B cells has shown therapeutic efficacy in treating autoantibody-related conditions, including RA. The development of B-cell-targeted therapies has led to a better understanding of the diverse roles of B cells in autoimmune diseases and their potential as effective treatment targets.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Article Rheumatology

Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis

Andrew R. Melville, Md Yuzaiful Md Yusof, John Fitton, Leticia Garcia-Montoya, Lynda Bailey, Shouvik Dass, Paul Emery, Maya H. Buch, Benazir Saleem

Summary: The study evaluated the impact of non-medical switch from rituximab originator (RTX-O) to biosimilar (RTX-B) in patients with rheumatoid arthritis. The results showed that non-medical switch to RTX-B was largely effective, with factors like comorbidities, previous biologic DMARDs, and RTX-O treatment history influencing switch decisions.

RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

B cell depletion impairs vaccination-induced CD8+ T cell responses in a type I interferon-dependent manner

Theresa Graalmann, Katharina Borst, Himanshu Manchanda, Lea Vaas, Matthias Bruhn, Lukas Graalmann, Mario Koster, Murielle Verboom, Michael Hallensleben, Carlos Alberto Guzman, Gerd Sutter, Reinhold E. Schmidt, Torsten Witte, Ulrich Kalinke

Summary: Rituximab-treated patients and B cell-deficient mice showed reduced expansion of virus-specific CD8(+) T cells after vaccination/infection with different vaccines/pathogens, indicating that B cells can modulate CD8(+) T cell responses. The choice of vaccines for B cell-depleted patients needs to be re-evaluated to effectively induce protective CD8(+) T cell responses.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Orthopedics

Association among B lymphocyte subset and rheumatoid arthritis in a Chinese population

Haiyan You, Mengwei Cheng, Cui Ma, Wenjuan Zheng, Yu Jiang, Di Chen, Yu Tang

Summary: This study explored differences in B lymphocyte subsets and cytokines in RA patients, finding that the percentage of plasmablasts was significantly higher in active RA patients. Plasmablast percentage was correlated with C reaction protein and could serve as an early diagnostic marker for RA. ROC curve analysis showed good specificity and sensitivity for diagnosing RA using the percentage of plasmablasts.

JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH (2021)

添加到收藏夹

Article Rheumatology

Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B-cells

Merel A. A. Opdam, J. H. de Leijer, Nathan den Broeder, Rogier M. Thurlings, Wilfred van der Weele, Michael T. Nurmohamed, Marc R. Kok, Lenny van Bon, David F. Ten Cate, Lise M. Verhoef, Alfons A. den Broeder

Summary: In this post hoc analysis of the REDO trial, it was found that potential mediators such as circulating B-cell counts, immunoglobulin levels, neutrophil counts, and drug use did not explain the observed dose-dependent infection risk. Additionally, a trend towards higher infection rates shortly after RTX infusion was identified.

RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020

Caitlin Norris-Grey, Geraldine Cambridge, Samantha Moore, Venkat Reddy, Maria Leandro

Summary: This study retrospectively reviewed the long-term persistence of rituximab in RA patients and identified factors associated with treatment discontinuation. The study found that many RA patients achieve good disease control with repeated cycles of rituximab treatment, but the main reason for discontinuation is treatment inefficacy. Seronegative patients and those who have previously failed other biologic DMARDs are at higher risk of drug discontinuation.

RHEUMATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity

James I. Robinson, Md Yuzaiful Md Yusof, Vinny Davies, Dawn Wild, Michael Morgan, John C. Taylor, Yasser El-Sherbiny, David L. Morris, Lu Liu, Andy C. Rawstron, Maya H. Buch, Darren Plant, Heather J. Cordell, John D. Isaacs, Ian N. Bruce, Paul Emery, Anne Barton, Timothy J. Vyse, Jennifer H. Barrett, Edward M. Vital, Ann W. Morgan, MATURA Consortia, MASTERPLANS Consortia

Summary: This study evaluated the impact of FCGR variants on clinical response and immune cell function in rituximab therapy. The study found that FCGR3A-158V variant and increased copy numbers were associated with better clinical response in rheumatoid arthritis patients. In systemic lupus erythematosus patients, FCGR3A-158V variant and FCGR2C-ORF copy numbers were associated with better clinical response. Furthermore, NK cell Fc gamma RIIIa expression and ADCC were associated with clinical response and B-cell depletion.

EBIOMEDICINE (2022)

添加到收藏夹

Article Rheumatology

Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis

Shigeru Iwata, Mingzeng Zhang, Maiko Hajime, Naoaki Ohkubo, Koshiro Sonomoto, Keiichi Torimoto, Yukihiro Kitanaga, Gulzhan Trimova, Yasuyuki Todoroki, Hiroko Miyata, Masanobu Ueno, Atsushi Nagayasu, Ryuichiro Kanda, Kazuhisa Nakano, Shingo Nakayamada, Kei Sakata, Yoshiya Tanaka

Summary: This study investigated the role of mTOR in B cells in rheumatoid arthritis, showing that mTOR activation in CXCR3(+) memory B cells is associated with disease activity and mediated through IL-6 production and RANKL expression. Additionally, treatment with TNF inhibitors had an impact on the association between CXCL10 and mTOR activated CXCR3(+) memory B cells.

RHEUMATOLOGY (2021)

添加到收藏夹

Article Immunology

Obinutuzumab in Kidney Transplantation: Effect on B-cell Counts and Crossmatch Tests

Mohamed M. NasrAllah, Mahmoud Elalfy, Mervat El Ansary, Yasser Elmeseery, Ihab Amer, Paolo Malvezzi, Lionel Rostaing

Summary: Obinutuzumab (OBZ) effectively reduced B-cell counts in kidney-transplant candidates and had no effect on CDC crossmatch results, unlike rituximab (RTX).

TRANSPLANTATION (2022)

添加到收藏夹

Article Rheumatology

Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience

Gerasimos Evangelatos, George E. Fragoulis, Kalliopi Klavdianou, Melina Moschopoulou, Dimitrios Vassilopoulos, Alexios Iliopoulos

Summary: The study found that 43% of rheumatoid arthritis patients treated with RTX developed HGG. Patients who developed low IgG or low IgM had lower baseline levels than those who did not, and the development of low IgM was associated with better disease outcomes.

RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Key interactions in the trimolecular complex consisting of the rheumatoid arthritis-associated DRB1*04:01 molecule, the major glycosylated collagen II peptide and the T-cell receptor

Changrong Ge, Sylvia Weisse, Bingze Xu, Doreen Dobritzsch, Johan Viljanen, Jan Kihlberg, Nhu-Nguyen Do, Nadine Schneider, Harald Lanig, Rikard Holmdahl, Harald Burkhardt

Summary: This study characterizes the autoantigen-presenting function of DRB1*04:01 and investigates T-cell responses to a specific peptide in patients with rheumatoid arthritis, revealing the importance of glycosylation of lysine residues in T-cell recognition.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Immunology

B cell depletion treatment decreases Th17 cells in patients with rheumatoid arthritis

Constantina A. Bounia, Stamatis-Nick C. Liossis

Summary: Treatment with rituximab (RTX) significantly reduces circulating Th17 cell percentages in patients with RA, while Tregs remain stable. Reduction of Th17 cells is particularly evident in responders to RTX treatment, ACPA+ and RF (-) patients with RA.

CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Rheumatology

Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry

Yann Nguyen, Xavier Mariette, Jacques E. Gottenberg, Michele Iudici, Jacques Morel, Olivier Vittecoq, Arnaud Constantin, Rene-Marc Flipo, Thierry Schaeverbeke, Jean Sibilia, Philippe Ravaud, Raphael Porcher, Raphaele Seror

Summary: This study found that only a small percentage of rheumatoid arthritis patients in real-life settings met all eligibility criteria from drug-registration trials. Non-eligible patients had lower treatment responses and higher risks of serious adverse events. The efficacy and safety data from registration trials may not be applicable to real-world RA patients receiving RTX treatment.

RHEUMATOLOGY (2023)

添加到收藏夹

Article Rheumatology

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

Maria Prendecki, Candice Clarke, Helena Edwards, Stacey McIntyre, Paige Mortimer, Sarah Gleeson, Paul Martin, Tina Thomson, Paul Randell, Anand Shah, Aran Singanayagam, Liz Lightstone, Alison Cox, Peter Kelleher, Michelle Willicombe, Stephen P. McAdoo

Summary: SARS-CoV-2 vaccines are immunogenic in patients receiving immunosuppression, though the response is impaired compared to healthy individuals. B-cell depletion following rituximab impairs serological responses, but T-cell responses are preserved in this group. Repeat vaccine doses for serological non-responders could be considered to induce more robust immunological response.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Letter Rheumatology

Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis

Serena Bugatti, Ludovico De Stefano, Ennio Giulio Favalli, Roberto Caporali, Carlomaurizio Montecucco

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Letter Rheumatology

Transient monoarthritis and psoriatic skin lesions following COVID-19

Ludovico De Stefano, Silvia Rossi, Carlomaurizio Montecucco, Serena Bugatti

ANNALS OF THE RHEUMATIC DISEASES (2023)

添加到收藏夹

Article Rheumatology

Cost-Effectiveness of the Early Arthritis Clinic Organizational Model

Anna Zanetti, Garifallia Sakellariou, Antonella Zambon, Greta Carrara, Lisa Argnani, Lorenzo G. Mantovani, Paolo A. Cortesi, Serena Bugatti, Carlomaurizio Montecucco, Carlo A. Scire

Summary: Early diagnosis and tight control improve outcomes of rheumatoid arthritis. This study compared the effectiveness and costs of an early arthritis clinic (EAC) with the current standard of care. The results showed that despite higher costs, the EAC reduced the number and length of hospitalizations and had higher adherence to quality-of-care guidelines.

ARTHRITIS CARE & RESEARCH (2023)

添加到收藏夹

Meeting Abstract Rheumatology

CYTOKINE PROFILE, HYPERFERRITINEMIA, AND MULTI-VISCERAL INVOLVEMENT CHARACTERISE MACROPHAGE ACTIVATION SYNDROME COMPLICATING ADULT ONSET STILL'S DISEASE. RESULTS FROM A MULTIDIMENSIONAL EVALUATION

P. Ruscitti, F. Ursini, O. Berardicurti, F. Masedu, E. Bozzalla Cassione, S. Naldi, I. Di Cola, C. Di Muzio, L. De Stefano, E. Di Nino, F. Sensini, L. Navarini, M. Vomero, S. Bugatti, M. Valenti, E. Mariani, A. Iagnocco, C. Montecucco, R. Giacomelli, P. Cipriani

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Meeting Abstract Rheumatology

PREVALENCE AND CHARACTERISTICS OF PATIENTS WITH ARTHRALGIA AT-RISK DEFINED ACCORDING TO THE RHEUMATOLOGIST AND THE NEW EULAR DEFINITION: A PILOT RETROSPECTIVE STUDY FOCUSSED ON REFERRAL TO A STRUCTURED EARLY ARTHRITIS CLINIC

S. Grignaschi, B. Xoxi, E. Bozzalla Cassione, T. Luvaro, M. I. Greco, I. Mazzucchelli, S. Bugatti, C. Montecucco, A. Manzo

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Meeting Abstract Rheumatology

A TEMPORARY ANTIRHEUMATIC DRUGS WITHDRAWAL DOES NOT CAUSE AN EXCESS OF DISEASE FLARES IN PATIENTS WITH PSORIATIC ARTHRITIS UNDERGOING COVID-19 MRNA VACCINATION

R. Bixio, A. Milanesi, O. Viapiana, C. Montecucco, S. Bugatti, M. Rossini

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Letter Rheumatology

A case of a rheumatoid nodule on the aortic valve in a patient with rheumatoid arthritis in sustained remission with anti-TNF alpha

L. De Stefano, M. Guerini, J. Pelizza, G. Ferracane, V Piccin, C. Montecucco, S. Bugatti

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Clinical Features of Diabetes Mellitus on Rheumatoid Arthritis: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group

Fabio Cacciapaglia, Francesca Romana Spinelli, Elena Bartoloni, Serena Bugatti, Gian Luca Erre, Marco Fornaro, Andreina Manfredi, Matteo Piga, Garifallia Sakellariou, Ombretta Viapiana, Fabiola Atzeni, Elisa Gremese

Summary: Rheumatoid arthritis (RA) and diabetes mellitus (DM) are both influenced by inflammation and have a connection in their development and progression. This study compared the characteristics of RA patients with and without DM, and found that DM patients were older and more commonly male, with higher BMI and weight. They were also less likely to use glucocorticoids and had higher HAQ scores. The study also highlighted the association between DM and RA, suggesting systemic inflammation as an underlying condition for both diseases.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Administrative Databases and Diagnostic Therapeutic and Assistance Paths-PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The of ATS Pavia

Giacomo M. Bruno, Maria Chiara Valentino, Alessandra Brunetti, Sergio Di Matteo, Ivan Begovic, Edoardo Croce, Garifallia Sakellariou, Serena Bugatti, Pietro Perotti, Silvia Vecchio, Simona Migliazza, Roberto Langella, Giorgio L. Colombo

Summary: The study aims to analyze the differences in health resource consumption between biological off-patent originator drugs and biosimilars in real clinical practice, specifically in the rheumatology area. By utilizing assisted databases, the study evaluates the differences in terms of resource consumption related to the drugs under analysis. The findings indicate an underuse of biosimilar drugs in the sample population.

PRAGMATIC AND OBSERVATIONAL RESEARCH (2023)

添加到收藏夹

Article Immunology

Tumor necrosis factor-α inhibitor-related autoimmune disorders

Ludovico De Stefano, Francesca Bobbio Pallavicini, Eleonora Mauric, Veronica Piccin, Enrico Maria Vismara, Carlomaurizio Montecucco, Serena Bugatti

Summary: Biotechnological monoclonal antibodies and receptor antagonists have emerged as an alternative therapy for treating systemic inflammatory diseases. However, immunotherapies may lead to the development of immune-mediated disorders. Understanding the phenomenon of the 'compensatory immunological switch' can help manage these disorders and interpret the heterogeneity of certain chronic inflammatory conditions.

AUTOIMMUNITY REVIEWS (2023)

添加到收藏夹

Review Rheumatology

Seronegative rheumatoid arthritis: one year in review 2023

L. De Stefano, B. D'Onofrio, S. Gandolfo, E. Bozzalla Cassione, D. Mauro, A. Manzo, F. Ciccia, S. Bugatti

Summary: In the past 20 years, earlier diagnosis and more intensive management have significantly improved the prognosis of rheumatoid arthritis, particularly in seropositive patients. However, seronegative rheumatoid arthritis remains surrounded by uncertainties, including its correct diagnosis, clinical phenotype, optimal treatment strategies, and relevant outcomes.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2023)

添加到收藏夹

Article Rheumatology

Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immuneinflammatory arthritis treated with biological and targeted synthetic disease-modifying anti- rheumatic drugs

L. De Stefano, S. Balduzzi, L. Bogliolo, B. D'Onofrio, M. di Lernia, E. Mauric, A. Milanesi, F. Brandolino, C. Rocca, S. Chiricolo, A. Manzo, C. Montecucco, S. Bugatti

Summary: This study evaluated the safety of COVID-19 vaccination in rheumatic patients treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). The results showed that the frequency and severity of systemic events after vaccination were similar to the general population, and no specific safety concerns emerged. Flares of the disease were reported by some patients, but most flares did not require treatment escalation or change.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2023)

添加到收藏夹

Article Rheumatology

Impact of csDMARDs adherence on clinical remission in patients with new-onset inflammatory arthritis: a prospective cohort study from the ELECTRA database

Anna Zanetti, Antonella Zambon, Carlo A. Scire, Serena Bugatti, Carlomaurizio Montecucco, Garifallia Sakellariou

Summary: This study aimed to evaluate the effect of adherence to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) on the achievement of clinical remission in patients with new-onset inflammatory arthritis. The results showed that patients with higher adherence to csDMARDs were more likely to achieve clinical remission.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2023)

添加到收藏夹

Letter Rheumatology

Do we need Early Arthritis Clinics to counteract the excess of mortality in rheumatoid arthritis?

G. Sakellariou, G. Carrara, A. Zanetti, C. A. Scire, S. Bugatti, C. Montecucco

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Increased COVID-19 mortality in patients with rheumatic diseases: results from the CONTROL-19 study by the Italian Society for Rheumatology

A. Zanetti, G. Carrara, G. Landolfi, D. Rozza, C. B. Chighizola, A. Alunno, L. Andreoli, R. Caporali, R. Gerli, G. D. Sebastiani, G. Valesini, L. Sinigaglia, B. Raffeiner, C. Lomater, M. Caprioli, M. Fredi, N. Romeo, G. Cuomo, M. Vadacca, C. A. Scire

Summary: This study investigated the differences in COVID-19 mortality between patients with rheumatic musculoskeletal diseases (RMD) and the general population in Italy. The results showed that patients with RMD had a higher risk of death compared to the general population, especially among younger patients and women.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.